UBS Initiates Coverage On Chimera Investment with Neutral Rating, Announces Price Target of $5.5
Benzinga Newsdesk 2 years ago
NewsPrice TargetInitiationAnalyst Ratings
UBS analyst Douglas Harter initiates coverage on Chimera Investment (NYSE:CIM) with a Neutral rating and announces Price Target of $5.5.
UBS analyst Douglas Harter initiates coverage on Chimera Investment (NYSE:CIM) with a Neutral rating and announces Price Target of $5.5.